Immix Biopharma, Inc.
News
(2)April 2026
Immix Biopharma, Inc. — DEF 14A Filing
Here's a clear breakdown of Immix Biopharma's (IMMX) proxy statement, focusing on what matters most to shareholders. # 🧾 What This Document Is This is a **Definitive Proxy Statement (DEF 14A)**. It's like an "invitation and instruction manual" for Immix Biopharma's 2026 Annual Meeting of Stockhold
Immix Biopharma, Inc. — ARS Filing
# 🧾 What This Document Is This is Immix Biopharma's **Annual Report (ARS)** for the fiscal year ended December 31, 2023. Think of it as the company's yearly "check-up" report to the SEC and its investors. It's a comprehensive look at their business, financial health, and progress on their goals ov
Peers in Biotechnology
Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.